新入荷 再入荷

Correlation of serum and local CXCL13 levels with disease severity in patients with non-traumatic osteonecrosis of femoral head | Journal of Orthopaedic Surgery and Research | Full Text

flash sale icon タイムセール
終了まで
00
00
00
999円以上お買上げで送料無料(
999円以上お買上げで代引き手数料無料
通販と店舗では販売価格や税表示が異なる場合がございます。また店頭ではすでに品切れの場合もございます。予めご了承ください。
新品 5780円 (税込)
数量

商品詳細情報

管理番号 新品 :6606211901
中古 :6606211901-1
メーカー f5ab2080f089e 発売日 2025-04-08 10:18 定価 6800円
カテゴリ

Correlation of serum and local CXCL13 levels with disease severity in patients with non-traumatic osteonecrosis of femoral head | Journal of Orthopaedic Surgery and Research | Full Text

Correlation of serum and local CXCL13 levels with disease severity in  patients with non-traumatic osteonecrosis of femoral head | Journal of  Orthopaedic Surgery and Research | Full TextCorrelation of serum and local CXCL13 levels with disease severity in patients with non-traumatic osteonecrosis of femoral head | Journal of Orthopaedic Surgery and Research | Full Text,Dr. Latency's Freak Report | Touhou Español | FandomDr. Latency's Freak Report | Touhou Español | Fandom,First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and  neck cancer: Japanese subgroup of KEYNOTE-048 | International Journal of  Clinical OncologyFirst-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048 | International Journal of Clinical Oncology,Magnolia kobus Extract Suppresses Porphyromonas gingivalis LPS-Induced  Proinflammatory Cytokine and MMP Expression in HGF-1 Cells and Regulates  Osteoclastogenesis in RANKL-Stimulated RAW264.7 CellsMagnolia kobus Extract Suppresses Porphyromonas gingivalis LPS-Induced Proinflammatory Cytokine and MMP Expression in HGF-1 Cells and Regulates Osteoclastogenesis in RANKL-Stimulated RAW264.7 Cells,Results of two Phase 1, Randomized, Double-blind, Placebo-controlled,  Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the  Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in  Healthy Participants Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants

 

商品情報の訂正

このページに記載された商品情報に記載漏れや誤りなどお気づきの点がある場合は、下記訂正依頼フォームよりお願い致します。

訂正依頼フォーム

商品レビュー

レビューの投稿にはサインインが必要です